Treatment response for the ITT population (all randomly assigned patients)
| Response . | Arm A (azacitidine + durvalumab) (n = 42) . | Arm B (azacitidine) (n = 42) . | P . | ||
|---|---|---|---|---|---|
| No. (%) . | 95% CI . | No. (%) . | 95% CI . | ||
| ORR (CR + PR + mCR + HI) | 26 (61.9) | 47.22-76.59 | 20 (47.6) | 32.51-62.72 | .1838 |
| CR | 3 (7.1) | 0.00-14.93 | 4 (9.5) | 0.65-18.40 | |
| mCR | 15 (35.7) | 21.22-50.21 | 8 (19.0) | 7.17-30.92 | |
| PR | 0 | 0 | |||
| HI only | 8 (19.0) | 7.17-30.92 | 8 (19.0) | 7.17-30.92 | |
| SD | 6 (14.3) | 3 (7.1) | |||
| Response . | Arm A (azacitidine + durvalumab) (n = 42) . | Arm B (azacitidine) (n = 42) . | P . | ||
|---|---|---|---|---|---|
| No. (%) . | 95% CI . | No. (%) . | 95% CI . | ||
| ORR (CR + PR + mCR + HI) | 26 (61.9) | 47.22-76.59 | 20 (47.6) | 32.51-62.72 | .1838 |
| CR | 3 (7.1) | 0.00-14.93 | 4 (9.5) | 0.65-18.40 | |
| mCR | 15 (35.7) | 21.22-50.21 | 8 (19.0) | 7.17-30.92 | |
| PR | 0 | 0 | |||
| HI only | 8 (19.0) | 7.17-30.92 | 8 (19.0) | 7.17-30.92 | |
| SD | 6 (14.3) | 3 (7.1) | |||
ITT, intent to treat; PR, partial remission; SD, stable disease.